-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof for use in a method of treating an individual with a sphingosine 1-phosphate subtype 1 (S1P 1) receptor-associated disorder; wherein the sphingosine 1-phosphate subtype 1 (S1P 1) receptor-associated disorder is selected from: an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury and acne; wherein the method comprises: administering to the individual in need thereof a pharmaceutical dosage form comprising a therapeutically effective amount of -2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[ b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein: the dosage form is administered under fed conditions; the therapeutically effective amount is equivalent to 0.5 to 5.0 mg of Compound 1; and the pharmaceutical dosage form has a mean fed/fasted ratio of the area under the plasma concentration versus time curve of from about 0.8 to about 1.25 and a mean fed/fasted ratio of the maximum plasma concentration (Cmax) from about 0.8 to about 1.25. wherein the sphingosine 1-phosphate subtype 1 (S1P 1) receptor-associated disorder is selected from: an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury and acne; wherein the method comprises: administering to the individual in need thereof a pharmaceutical dosage form comprising a therapeutically effective amount of -2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[ b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein: the dosage form is administered under fed conditions; the therapeutically effective amount is equivalent to 0.5 to 5.0 mg of Compound 1; and the pharmaceutical dosage form has a mean fed/fasted ratio of the area under the plasma concentration versus time curve of from about 0.8 to about 1.25 and a mean fed/fasted ratio of the maximum plasma concentration (Cmax) from about 0.8 to about 1.25. administering to the individual in need thereof a pharmaceutical dosage form comprising a therapeutically effective amount of -2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[ b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein: the dosage form is administered under fed conditions; the therapeutically effective amount is equivalent to 0.5 to 5.0 mg of Compound 1; and the pharmaceutical dosage form has a mean fed/fasted ratio of the area under the plasma concentration versus time curve of from about 0.8 to about 1.25 and a mean fed/fasted ratio of the maximum plasma concentration (Cmax) from about 0.8 to about 1.25. the dosage form is administered under fed conditions; the therapeutically effective amount is equivalent to 0.5 to 5.0 mg of Compound 1; and the pharmaceutical dosage form has a mean fed/fasted ratio of the area under the plasma concentration versus time curve of from about 0.8 to about 1.25 and a mean fed/fasted ratio of the maximum plasma concentration (Cmax) from about 0.8 to about 1.25.